Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...